Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation

There are no standard treatments to prevent or hasten the recovery from severe conditioning-regimen–induced thrombocytopenia occurring after autologous hematopoietic cell transplantation (auto-HCT). We conducted an open-label, single-arm pilot study of romiplostim, a thrombopoietin receptor agonist,...

Descripción completa

Detalles Bibliográficos
Autores principales: Scordo, Michael, Gilbert, Leah J., Hanley, Danielle M., Flynn, Jessica R., Devlin, Sean M., Nguyen, Linh K., Ruiz, Josel D., Shah, Gunjan L., Sauter, Craig S., Chung, David J., Landau, Heather J., Lahoud, Oscar B., Lin, Richard J., Dahi, Parastoo B., Perales, Miguel-Angel, Giralt, Sergio A., Soff, Gerald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130608/
https://www.ncbi.nlm.nih.gov/pubmed/36409612
http://dx.doi.org/10.1182/bloodadvances.2022007838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130608/
https://www.ncbi.nlm.nih.gov/pubmed/36409612
http://dx.doi.org/10.1182/bloodadvances.2022007838

Ejemplares similares